United States of America based
EVQLV develops artificial intelligence, engineered with life science data, to accelerate how biologic therapies reach patients. We work with partners at the discovery stage to accelerate the speed of antibody discovery. For those collaborators who have preclinical, clinical, or commercial assets, we support the optimization of antibody candidates, develop assets that expand IP protection, and design next generation and innovative immunotherapies. All of our work is performed at accelerated speeds only feasible by leveraging computational tools that learn from massive and diverse data points.
TechnologiesAI Companies (Drug Discovery)
No pipelines published yet
No services posted yet